Helicobacter pylori vaccine: mucosal adjuvant & delivery systems.
Article
in English
| IMSEAR
| ID: sea-135873
ABSTRACT
Vaccination, especially mucosal vaccination, is considered to be effective in the management of Helicobacter pylori infections. However, most antigens alone cannot induce immune responses when administered mucosally and need to be co-administered with adjuvants or delivery systems. The current research on the mucosal adjuvant and delivery systems of vaccine against H. pylori, including advantages and disadvantages, mechanisms and applications is discussed in this review. Mutants of cholera toxin (CT) and the heat labile enterotoxin of Escherichia coli (LT), CpG oligodeoxynucleotides, biocompatible and biodegradable polymers, and live attenuated bacterial vectors may be promising adjuvant and delivery systems for H. pylori vaccine.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Humans
/
Drug Carriers
/
Bacterial Vaccines
/
Adjuvants, Immunologic
/
Cholera Toxin
/
Helicobacter pylori
/
Helicobacter Infections
/
Enterotoxins
/
Animals
/
Mucous Membrane
Language:
English
Year:
2009
Type:
Article
Similar
MEDLINE
...
LILACS
LIS